Understanding how proteins, enzymes, and therapeutic antibodies perform their biological roles is essential at every stage of drug development. From characterizing enzyme kinetics and molecular binding events to evaluating antibody-mediated effector functions and cellular potency, functional and binding assays provide the quantitative data that drives critical decisions. At Profacgen, our integrated assay platform delivers reproducible, regulatory-ready results across the full spectrum of functional and binding analysis.
Our comprehensive enzyme activity platform covers quantitative kinetic characterization, inhibitor and activator screening, and high-throughput compound evaluation across all major enzyme families. We deploy multiple detection modalities—including fluorescence, luminescence, LC-MS/MS, colorimetric, and radiometric methods—to match the catalytic properties of your target and the sensitivity requirements of your project. From single-enzyme Km and kcat determination to 384/1536-well screening campaigns, our experienced enzymology team delivers robust data for drug discovery, biomarker validation, and metabolic studies.
We provide specialized complement system assays to evaluate the classical, lectin, and alternative activation pathways. Our services include complement component quantification (C1q, C3b, C4, C5a, and others), functional complement activity assays, and complement-dependent cytotoxicity (CDC) evaluation for therapeutic antibody development. These assays are critical for immunogenicity assessment, biosafety testing, and characterizing the immunomodulatory properties of biologics.
Profacgen offers a full suite of label-free and labeled technologies for quantifying biomolecular interactions with high precision. Our platform includes surface plasmon resonance (SPR), bio-layer interferometry (BLI), fluorescence polarization, and microscale thermophoresis (MST) for affinity and kinetics determination. We also provide electrophoretic mobility shift assays (EMSA), pull-down assays, and co-immunoprecipitation (Co-IP) services for validating protein-protein, protein-DNA, and protein-RNA interactions.
Our cell-based assay platforms evaluate cellular responses, signaling pathways, and biological potency in physiologically relevant contexts. We offer GPCR functional screening, cell-based kinase assays, reporter gene assays, and high-content screening (HCS) for compound characterization. These assays are designed to bridge the gap between biochemical data and in vivo efficacy, providing predictive insights for lead optimization and regulatory submissions.
We specialize in characterizing Fc-mediated effector functions that define the therapeutic profile of monoclonal antibodies and Fc-fusion proteins. Our services include antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and Fc receptor binding assays (FcγRI, FcγRII, FcγRIII, and FcRn). These assays are essential for Fc engineering, biosimilar comparability, and meeting regulatory requirements for antibody therapeutic development.
Contact us today to discover how Profacgen's Functional & Binding Assays can accelerate your drug development program with reliable, quantitative insights.
Fill out this form and one of our experts will respond to you within one business day.